Lung Cancer Assessment Using MR Imaging: An Update

Magnetic Resonance Imaging Clinics of North America

Volumn 23, Issue 2, 2015, Pages 231-244

  Ohno, Yoshiharu ^a   Koyama, Hisanobu ^a   Yoshikawa, Takeshi ^a   Matsumoto, Sumiaki ^a   Sugimura, Kazuro ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Lung cancer; MR imaging; Nodules; Staging; Therapeutic effect

Indexed keywords

ANTINEOPLASTIC AGENT;

ADRENAL METASTASIS; BONE SCINTISCANNING; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CARDIAC GATED IMAGING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONSERVATIVE TREATMENT; DIAGNOSTIC ACCURACY; DIFFUSION WEIGHTED IMAGING; DRUG EFFECT; HUMAN; INTERMETHOD COMPARISON; LUNG CANCER; LUNG FUNCTION; LUNG METASTASIS; LUNG NODULE; LYMPH NODE METASTASIS; MAGNETIC RESONANCE ANGIOGRAPHY; NON SMALL CELL LUNG CANCER; NUCLEAR MAGNETIC RESONANCE IMAGING; PERFUSION WEIGHTED IMAGING; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE PERIOD; PREDICTION; REVIEW; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THERAPY EFFECT; THORAX RADIOGRAPHY; TUMOR DIFFERENTIATION; WHOLE BODY MRI; AGED; DIFFERENTIAL DIAGNOSIS; FEMALE; LUNG DISEASES; LUNG NEOPLASMS;

AGED; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; LUNG DISEASES; LUNG NEOPLASMS; MAGNETIC RESONANCE IMAGING; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84929326365     PISSN: 10649689     EISSN: 15579786     Source Type: Journal    
DOI: 10.1016/j.mric.2015.01.012     Document Type: Review

References (90)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012, 62:10-29.
2. Melamed M.R., Flehinger B.J., Zaman M.B. Impact of early detection on the clinical course of lung cancer. Surg Clin North Am 1987, 67:909-924.
3. Nahmias C., Hanna W.T., Wahl L.M., et al. Time course of early response to chemotherapy in non-small cell lung cancer patients with 18F-FDG PET/CT. JNucl Med 2007, 48:744-751.
4. Geddes D.M. The natural history of lung cancer: a review based on rates of tumour growth. Br J Dis Chest 1979, 73:1-17.
5. Spiro S.G., Silvestri G.A. One hundred years of lung cancer. Am J Respir Crit Care Med 2005, 172:523-529.
6. Allen M.S., Darling G.E., Pechet T.T., ACOSOG Z0030 Study Group, et al. Morbidity and mortality of major pulmonary resections in patients with early-stage lung cancer: initial results of the randomized, prospective ACOSOG Z0030 trial. Ann Thorac Surg 2006, 81:1013-1019.
7. National Lung Screening Trial Research Team, Aberle D.R., Adams A.M., et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. NEngl J Med 2011, 365:395-409.
8. Sakai F., Sone S., Maruyama A., et al. Thin-rim enhancement in Gd-DTPA-enhanced magnetic resonance images of tuberculoma: a new finding of potential differential diagnostic importance. JThorac Imaging 1992, 7:64-69.
9. Sakai F., Sone S., Kiyono K., et al. MR of pulmonary hamartoma: pathologic correlation. JThorac Imaging 1994, 9(1):51-55.
10. Fujimoto K., Meno S., Nishimura H., et al. Aspergilloma within cavitary lung cancer: MR imaging findings. AJR Am J Roentgenol 1994, 163(3):565-567.
11. Blum U., Windfuhr M., Buitrago-Tellez C., et al. Invasive pulmonary aspergillosis. MRI, CT, and plain radiographic findings and their contribution for early diagnosis. Chest 1994, 106(4):1156-1161.
12. Chung M.H., Lee H.G., Kwon S.S., et al. MR imaging ofsolitary pulmonary lesion: emphasis on tuberculomas and comparison with tumors. JMagn Reson Imaging 2000, 11(6):629-637.
13. Gaeta M., Minutoli F., Ascenti G., et al. MR white lung sign: incidence and significance in pulmonary consolidations. JComput Assist Tomogr 2001, 25(6):890-896.
14. Gaeta M., Vinci S., Minutoli F., et al. CT and MRI findings of mucin-containing tumors and pseudotumors of the thorax: pictorial review. Eur Radiol 2002, 12(1):181-189.
15. Ohno Y., Sugimura K., Hatabu H. MR imaging of lung cancer. Eur J Radiol 2002, 44(3):172-181.
16. Sieren J.C., Ohno Y., Koyama H., et al. Recent technological and application developments in computed tomography and magnetic resonance imaging for improved pulmonary nodule detection and lung cancer staging. JMagn Reson Imaging 2010, 32(6):1353-1369.
17. Kono M., Adachi S., Kusumoto M., et al. Clinical utility of Gd-DTPA-enhanced magnetic resonance imaging in lung cancer. JThorac Imaging 1993, 8(1):18-26.
18. Kusumoto M., Kono M., Adachi S., et al. Gadopentetate-dimeglumine-enhanced magnetic resonance imaging for lung nodules. Differentiation of lung cancer and tuberculoma. Invest Radiol 1994, 29(Suppl 2):S255-S256.
19. Koyama H., Ohno Y., Kono A., et al. Quantitative and qualitative assessment of non-contrast-enhanced pulmonary MR imaging for management of pulmonary nodules in 161 subjects. Eur Radiol 2008, 18(10):2120-2131.
20. Mori T., Nomori H., Ikeda K., et al. Diffusion-weighted magnetic resonance imaging for diagnosing malignant pulmonary nodules/masses: comparison with positron emission tomography. JThorac Oncol 2008, 3(4):358-364.
21. Satoh S., Kitazume Y., Ohdama S., et al. Can malignant and benign pulmonary nodules be differentiated with diffusion-weighted MRI?. AJR Am J Roentgenol 2008, 191(2):464-470.
22. Uto T., Takehara Y., Nakamura Y., et al. Higher sensitivity and specificity for diffusion-weighted imaging of malignant lung lesions without apparent diffusion coefficient quantification. Radiology 2009, 252(1):247-254.
23. Cronin P., Dwamena B.A., Kelly A.M., et al. Solitary pulmonary nodules: meta-analytic comparison of cross-sectional imaging modalities for diagnosis of malignancy. Radiology 2008, 246(3):772-782.
24. Guckel C., Schnabel K., Deimling M., et al. Solitary pulmonary nodules: MR evaluation of enhancement patterns with contrast-enhanced dynamic snapshot gradient-echo imaging. Radiology 1996, 200(3):681-686.
25. Ohno Y., Hatabu H., Takenaka D., et al. Solitary pulmonary nodules: potential role of dynamic MR imaging in management initial experience. Radiology 2002, 224(2):503-511.
26. Fujimoto K., Abe T., Muller N.L., et al. Small peripheral pulmonary carcinomas evaluated with dynamic MR imaging: correlation with tumor vascularity and prognosis. Radiology 2003, 227(3):786-793.
27. Ohno Y., Hatabu H., Takenaka D., et al. Dynamic MR imaging: value of differentiating subtypes of peripheral small adenocarcinoma of the lung. Eur J Radiol 2004, 52(2):144-150.
28. Schaefer J.F., Vollmar J., Schick F., et al. Solitary pulmonary nodules: dynamic contrast-enhanced MR imaging-perfusion differences in malignant and benign lesions. Radiology 2004, 232(2):544-553.
29. Kono R., Fujimoto K., Terasaki H., et al. Dynamic MRI of solitary pulmonary nodules: comparison of enhancement patterns of malignant and benign small peripheral lung lesions. AJR Am J Roentgenol 2007, 188(1):26-36.
30. Ohno Y., Koyama H., Takenaka D., et al. Dynamic MRI, dynamic multidetector-row computed tomography (MDCT), and coregistered 2-[fluorine-18]-fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET)/CT: comparative study of capability for management of pulmonary nodules. JMagn Reson Imaging 2008, 27(6):1284-1295.
31. Ohno Y., Nishio M., Koyama H., et al. Dynamic contrast-enhanced CT and MRI for pulmonary nodule assessment. AJR Am J Roentgenol 2014, 202:515-529.
32. Gámez C., Rosell R., Fernández A., et al. PET/CT fusion scan in lung cancer: current recommendations and innovations. JThorac Oncol 2006, 1:74-77.
33. Silvestri G.A., Gould M.K., Margolis M.L., American College of Chest Physicians, et al. Noninvasive staging of non-small cell lung cancer: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest 2007, 132:178S-201S.
34. Samson D.J., Seidenfeld J., Simon G.R., American College of Chest Physicians, et al. Evidence for management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007, 132:314S-323S.
35. Silvestri G.A., Gonzalez A.V., Jantz M.A., et al. Methods for staging non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013, 143:e211S-e250S.
36. Webb W.R., Gatsonis C., Zerhouni E.A., et al. CT and MR imaging in staging non-small cell bronchogenic carcinoma: report of the radiologic diagnostic oncology group. Radiology 1991, 178(3):705-713.
37. Koyama H., Ohno Y., Seki S., et al. Magnetic resonance imaging for lung cancer. JThorac Imaging 2013, 28:138-150.
38. Ohno Y. New applications of magnetic resonance imaging for thoracic oncology. Semin Respir Crit Care Med 2014, 35:27-40.
39. Sakai S., Murayama S., Murakami J., et al. Bronchogenic carcinoma invasion of the chest wall: evaluation with dynamic cine MRI during breathing. JComput Assist Tomogr 1997, 21(4):595-600.
40. Murata K., Takahashi M., Mori M., et al. Chest wall and mediastinal invasion by lung cancer: evaluation with multisection expiratory dynamic CT. Radiology 1994, 191(1):251-255.
41. Takahashi K., Furuse M., Hanaoka H., et al. Pulmonary vein and left atrial invasion by lung cancer: assessment by breath-hold gadolinium-enhanced three-dimensional MR angiography. JComput Assist Tomogr 2000, 24:557-561.
42. Ohno Y., Adachi S., Motoyama A., et al. Multiphase ECG-triggered 3D contrast-enhanced MR angiography: utility for evaluation of hilar and mediastinal invasion of bronchogenic carcinoma. JMagn Reson Imaging 2001, 13:215-224.
43. Boiselle P.M., Patz E.F., Vining D.J., et al. Imaging of mediastinal lymph nodes: CT, MR, and FDG PET. Radiographics 1998, 18:1061-1069.
44. Takenaka D., Ohno Y., Hatabu H., et al. Differentiation of metastatic versus non-metastatic mediastinal lymph nodes in patients with non-small cell lung cancer using respiratory-triggered short inversion time inversion recovery (STIR) turbo spin-echo MR imaging. Eur J Radiol 2002, 44(3):216-224.
45. Ohno Y., Hatabu H., Takenaka D., et al. Metastases in mediastinal and hilar lymph nodes in patients with non-small cell lung cancer: quantitative and qualitative assessment with STIR turbo spin-echo MR imaging. Radiology 2004, 231(3):872-879.
46. Ohno Y., Koyama H., Nogami M., et al. STIR turbo SE MR imaging vs. coregistered FDG-PET/CT: quantitative and qualitative assessment of N-stage in non-small-cell lung cancer patients. JMagn Reson Imaging 2007, 26(4):1071-1080.
47. Yi C.A., Shin K.M., Lee K.S., et al. Non-small cell lung cancer staging: efficacy comparison of integrated PET/CT versus 3.0-T whole-body MR imaging. Radiology 2008, 248(2):632-642.
48. Morikawa M., Demura Y., Ishizaki T., et al. The effectiveness of 18F-FDG PET/CT combined with STIR MRI for diagnosing nodal involvement in the thorax. JNucl Med 2009, 50(1):81-87.
49. Ohno Y., Koyama H., Yoshikawa T., et al. Nstage disease in patients with non-small cell lung cancer: efficacy of quantitative and qualitative assessment with STIR turbo spin-echo imaging, diffusion-weighted MR imaging, and fluorodeoxyglucose PET/CT. Radiology 2011, 261(2):605-615.
50. Nomori H., Mori T., Ikeda K., et al. Diffusion-weighted magnetic resonance imaging can be used in place of positron emission tomography for N staging of non-small cell lung cancer with fewer false-positive results. JThorac Cardiovasc Surg 2008, 135(4):816-822.
51. Hasegawa I., Boiselle P.M., Kuwabara K., et al. Mediastinal lymph nodes in patients with non-small cell lung cancer: preliminary experience with diffusion-weighted MR imaging. JThorac Imaging 2008, 23(3):157-161.
52. 18F]-FDG PET/CT for N-staging in patients with lung cancer. Eur J Radiol 2012, 81(1):178-182.
53. Feuerstein I.M., Jicha D.L., Pass H.I., et al. Pulmonary metastases: MR imaging with surgical correlation. A prospective study. Radiology 1992, 182:123-129.
54. Kersjes W., Mayer E., Buchenroth M., et al. Diagnosis of pulmonary metastases with turbo-SE MR imaging. Eur Radiol 1997, 7:1190-1194.
55. Schroeder T., Ruehm S.G., Debatin J.F., et al. Detection of pulmonary nodules using a 2D HASTE MR sequence: comparison with MDCT. AJR Am J Roentgenol 2005, 185:979-984.
56. Both M., Schultze J., Reuter M., et al. Fast T1- and T2-weighted pulmonary MR-imaging in patients with bronchial carcinoma. Eur J Radiol 2005, 53:478-488.
57. Regier M., Kandel S., Kaul M.G., et al. Detection of small pulmonary nodules in high-field MR at 3 T: evaluation of different pulse sequences using porcine lung explants. Eur Radiol 2007, 17:1341-1351.
58. Bruegel M., Gaa J., Woertler K., et al. MRI of the lung: value of different turbo spin-echo, single-shot turbo spin-echo, and 3D gradient-echo pulse sequences for the detection of pulmonary metastases. JMagn Reson Imaging 2007, 25:73-81.
59. Yi C.A., Jeon T.Y., Lee K.S., et al. 3-T MRI: usefulness for evaluating primary lung cancer and small nodules in lobes not containing primary tumors. AJR Am J Roentgenol 2007, 189:386-392.
60. Frericks B.B., Meyer B.C., Martus P., et al. MRI of the thorax during whole-body MRI: evaluation of different MR sequences and comparison to thoracic multidetector computed tomography (MDCT). JMagn Reson Imaging 2008, 27:538-545.
61. Sommer G., Tremper J., Koenigkam-Santos M., et al. Lung nodule detection in a high-risk population: comparison of magnetic resonance imaging and low-dose computed tomography. Eur J Radiol 2014, 83:600-605.
62. Ohno Y., Koyama H., Nogami M., et al. Whole-body MR imaging vs. FDG-PET: comparison of accuracy of M-stage diagnosis for lung cancer patients. JMagn Reson Imaging 2007, 26(3):498-509.
63. Ohno Y., Koyama H., Onishi Y., et al. Non-small cell lung cancer: whole-body MR examination for M-stage assessment-utility for whole-body diffusion-weighted imaging compared with integrated FDG PET/CT. Radiology 2008, 248(2):643-654.
64. Takenaka D., Ohno Y., Matsumoto K., et al. Detection of bone metastases in non-small cell lung cancer patients: comparison of whole-body diffusion-weighted imaging (DWI), whole-body MR imaging without and with DWI, whole-body FDG-PET/CT, and bone scintigraphy. JMagn Reson Imaging 2009, 30(2):298-308.
65. Sommer G., Wiese M., Winter L., et al. Preoperative staging of non-small-cell lung cancer: comparison of whole-body diffusion-weighted magnetic resonance imaging and 18F-fluorodeoxyglucose-positron emission tomography/computed tomography. Eur Radiol 2012, 22(12):2859-2867.
66. Schwenzer N.F., Schraml C., Müller M., et al. Pulmonary lesion assessment: comparison of whole-body hybrid MR/PET and PET/CT imaging-pilot study. Radiology 2012, 264:551-558.
67. Kohan A.A., Kolthammer J.A., Vercher-Conejero J.L., et al. Nstaging of lung cancer patients with PET/MRI using a three-segment model attenuation correction algorithm: initial experience. Eur Radiol 2013, 23:3161-3169.
68. Heusch P., Buchbender C., Köhler J., et al. Thoracic staging in lung cancer: prospective comparison of 18F-FDG PET/MR imaging and 18F-FDG PET/CT. JNucl Med 2014, 55:373-378.
69. Ohno Y., Nishio M., Koyama H., et al. Comparison of the utility of whole-body MRI with and without contrast-enhanced Quick 3D and double RF fat suppression techniques, conventional whole-body MRI, PET/CT and conventional examination for assessment of recurrence in NSCLC patients. Eur J Radiol 2013, 82:2018-2027.
70. Pierce R.J., Copland J.M., Sharpe K., et al. Preoperative risk evaluation for lung cancer resection: predicted postoperative product as a predictor of surgical mortality. Am J Respir Crit Care Med 1994, 150:947-955.
71. Bolliger C.T., Jordan P., Solèr M., et al. Exercise capacity as a predictor of postoperative complications in lung resection candidates. Am J Respir Crit Care Med 1995, 151:1472-1480.
72. Wyser C., Stulz P., Soler M., et al. Prospective evaluation of an algorithm for the functional assessment of lung resection candidates. Am J Respir Crit Care Med 1999, 159:1450-1456.
73. Mazzone P.J., Arroliga A.C. Lung cancer: preoperative pulmonary evaluation of the lung resection candidate. Am J Med 2005, 118:578-583.
74. Colice G.L., Shafazand S., Griffin J.P., American College of Chest Physicians, et al. Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest 2007, 132(3 Suppl):161S-177S.
75. Iwasawa T., Saito K., Ogawa N., et al. Prediction of postoperative pulmonary function using perfusion magnetic resonance imaging of the lung. JMagn Reson Imaging 2002, 15:685-692.
76. Ohno Y., Hatabu H., Higashino T., et al. Dynamic perfusion MRI versus perfusion scintigraphy: prediction of postoperative lung function in patients with lung cancer. AJR Am J Roentgenol 2004, 182:73-78.
77. Ohno Y., Koyama H., Nogami M., et al. Postoperative lung function in lung cancer patients: comparative analysis of predictive capability of MRI, CT, and SPECT. AJR Am J Roentgenol 2007, 189:400-408.
78. Ohno Y., Koyama H., Nogami M., et al. State-of-the-art radiological techniques improve the assessment of postoperative lung function in patients with non-small cell lung cancer. Eur J Radiol 2011, 77:97-104.
79. Ohno Y., Hatabu H., Higashino T., et al. Oxygen-enhanced MR imaging: correlation with postsurgical lung function in patients with lung cancer. Radiology 2005, 236:704-711.
80. Eisenhauer E.A., Therasse P., Bogaerts J., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45:228-247.
81. Ohno Y., Adachi S., Kono M., et al. Predicting the prognosis of non-small cell lung cancer patient treated with conservative therapy using contrast-enhanced MR imaging. Eur Radiol 2000, 10:1770-1781.
82. Ohno Y., Nogami M., Higashino T., et al. Prognostic value of dynamic MR imaging for non-small-cell lung cancer patients after chemoradiotherapy. JMagn Reson Imaging 2005, 21:775-783.
83. de Langen A.J., van den Boogaart V., Lubberink M., et al. Monitoring response to antiangiogenic therapy in non-small cell lung cancer using imaging markers derived from PET and dynamic contrast-enhanced MRI. JNucl Med 2011, 52:48-55.
84. Giesel F.L., Bischoff H., von Tengg-Kobligk H., et al. Dynamic contrast-enhanced MRI of malignant pleural mesothelioma: a feasibility study of noninvasive assessment, therapeutic follow-up, and possible predictor of improved outcome. Chest 2006, 129:1570-1576.
85. Giesel F.L., Choyke P.L., Mehndiratta A., et al. Pharmacokinetic analysis of malignant pleural mesothelioma-initial results of tumor microcirculation and its correlation to microvessel density (CD-34). Acad Radiol 2008, 15:563-570.
86. Kelly R.J., Rajan A., Force J., et al. Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib. Clin Cancer Res 2011, 17:1190-1199.
87. Yabuuchi H., Hatakenaka M., Takayama K., et al. Non-small cell lung cancer: detection of early response to chemotherapy by using contrast-enhanced dynamic and diffusion-weighted MR imaging. Radiology 2011, 261:598-604.
88. Ohno Y., Koyama H., Yoshikawa T., et al. Diffusion-weighted MRI versus 18F-FDG PET/CT: performance as predictors of tumor treatment response and patient survival in patients with non-small cell lung cancer receiving chemoradiotherapy. AJR Am J Roentgenol 2012, 198:75-82.
89. Nishino M., Hatabu H., Johnson B.E., et al. State of the art: response assessment in lung cancer in the era of genomic medicine. Radiology 2014, 271:6-27.
90. Hiraoka M., Akuta K., Nishimura Y., et al. Tumor response to thermoradiation therapy: use of CT in evaluation. Radiology 1987, 164:259-262.